A Phase 3 interventional study of Placebo and Alirocumab in Heterozygous Familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-01.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 48th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2015, is one of 30 in phase 3, and was the 28th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
Brigham and Women's Hospital · Sites in United States
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 34 · Phase 4 4
First in 1985; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 68 interventional studies, 22 across the 8 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 76 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 3 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperlipoproteinemia Type II with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05284513Geisinger ClinicCollaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) | 2027-01 |
| NCT05750667Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia | 2027-02-28 |
| NCT07919353Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 | 2027-02-28 |
| NCT06743659Brigham and Women's HospitalComputerized Decision Support for Identification and Management of Familial Hypercholesterolemia | 2027-03-30 |
| NCT06439654Atlantic Health SystemAtlantic Lipid Lowering Treatment Optimization Program | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments in participants with heterozygous familial hypercholesterolemia (HeFH) undergoing weekly or bi-weekly LDL apheresis therapy.
LDL apheresis removes low-density lipoproteins (LDL) that transport cholesterol in the plasma portion of the blood. This treatment is mainly used for familial hypercholesterolemia, but can be used in other rare diseases. Familial hypercholesterolemia (HeFH) is an inherited genetic condition that causes accumulation of cholesterol in the blood, which can lead to atherosclerosis and heart disease. This treatment is recommended for patients who do not respond to dietary and/or medication control of LDL cholesterol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
Drug: Placebo
Alirocumab 150 mg SC injection Q2W up to Week 16.
Drug: Alirocumab
Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
Drug: Alirocumab
Also known as: REGN727, SAR236553, Praluent®
Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18
Rate of apheresis treatments were normalized by the number of planned apheresis treatments according to each participant's established schedule at screening, week -10 to week -2. The normalized rate of apheresis was defined for each participant as the number of actual apheresis treatments received from week 7 to week 18 divided by the number of planned apheresis treatments per randomization strata at baseline (6 for Q2W and 12 for QW).
Time frame: Week 7 to Week 18 (before start of open-label treatment)
Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6
Adjusted Least-squares (LS) means and standard errors at Week 6 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 2 to Week 18 regardless of status on or off-treatment were used in the model (ITT analysis).
Time frame: Baseline and at Week 6
Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 18
Rate of apheresis treatments were normalized by the rate by the number of actual apheresis treatments according to received from week 15 to week 18 divided by the planned apheresis treatments per randomization strata at baseline (2 for Q2W and 4 for QW). Only legitimate apheresis treatment skipping per point-of-care LDL-C value is counted as "apheresis not occurred". Missing apheresis treatment information (any reason) from week 7 to week 18 is assigned an outcome of the apheresis treatment occurred at the visit (i.e. impute 1 apheresis treatment for that visit).
Time frame: Week 15 up to Week 18 (before the start of open-label treatment dose)
Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6
Percentage of participants at Week 6 was obtained from a last observation carried forward (LOCF) model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6
Percentage of participants at Week 6 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18
Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18
Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18
The W-BQ22 (well-being) questionnaire was a standardized and generic instrument used for measuring the impact of hypercholesterolemia and treatment on well-being of participants. The general well-being score was calculated as the sum of 22 questions in the W-BQ22 questionnaire (each question scored from 0 to 3 \[0 = not at all and 3 = all the time\]). Total score for 22 questions range from 0 to 66 \[0 = worst condition and 66 = best well-being condition).
Time frame: From Baseline to Week 18
Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6
Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6
Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 6
Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18
Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 18
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 18
Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 18
The study was conducted in Germany and the United States between 09 Mar 2015 and 20 Apr 2016. A total of 76 participants were screened, of which 62 were enrolled and randomized in the study.
| Milestone | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Alirocumab 150 Q2W (Open Label Treatment Period) |
|---|---|---|---|
| Started | 21 | 41 | 0 |
| Completed | 20 | 37 | 0 |
| Not completed | 1 | 4 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Milestone | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Alirocumab 150 Q2W (Open Label Treatment Period) |
|---|---|---|---|
| Started | 0 | 0 | 29 |
| Completed | 0 | 0 | 27 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Rate of apheresis treatments were normalized by the number of planned apheresis treatments according to each participant's established schedule at screening, week -10 to week -2. The normalized rate of apheresis was defined for each participant as the number of actual apheresis treatments received from week 7 to week 18 divided by the number of planned apheresis treatments per randomization strata at baseline (6 for Q2W and 12 for QW).
| Treatments | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18 | 0.806 ± 0.191 | 0.128 ± 0.242 |
Adjusted Least-squares (LS) means and standard errors at Week 6 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 2 to Week 18 regardless of status on or off-treatment were used in the model (ITT analysis).
| percent change in mmol/L | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6 | 1.6 ± 3.1 | -53.7 ± 2.3 |
Rate of apheresis treatments were normalized by the rate by the number of actual apheresis treatments according to received from week 15 to week 18 divided by the planned apheresis treatments per randomization strata at baseline (2 for Q2W and 4 for QW). Only legitimate apheresis treatment skipping per point-of-care LDL-C value is counted as "apheresis not occurred". Missing apheresis treatment information (any reason) from week 7 to week 18 is assigned an outcome of the apheresis treatment occurred at the visit (i.e. impute 1 apheresis treatment for that visit).
| Treatments | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 18 | 0.774 ± 0.315 | 0.165 ± 0.334 |
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6 | 1.2 ± 3 | -42.8 ± 2.1 |
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6 | 2.8 ± 2.9 | -47.1 ± 2.1 |
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6 | 3.1 ± 2.5 | -36.4 ± 1.8 |
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6 | 0 ± 3.3 | 4.2 ± 2.4 |
Percentage of participants at Week 6 was obtained from a last observation carried forward (LOCF) model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
| percentage of participants | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6 | 4.8 | 95.1 |
Percentage of participants at Week 6 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
| percentage of participants | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6 | 0 | 63.4 |
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18 | 4 ± 6.2 | -42.3 ± 4.5 |
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18 | 1.7 ± 4.8 | -33.8 ± 3.5 |
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18 | 4.7 ± 5.6 | -35.7 ± 4.1 |
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18 | 4.7 ± 4.7 | -27.1 ± 3.4 |
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18 | -0.7 ± 3.4 | 7.8 ± 2.4 |
Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
| percentage of participants | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18 | 0 | 65.9 |
Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).
| percentage of participants | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18 | 0 | 43.9 |
The W-BQ22 (well-being) questionnaire was a standardized and generic instrument used for measuring the impact of hypercholesterolemia and treatment on well-being of participants. The general well-being score was calculated as the sum of 22 questions in the W-BQ22 questionnaire (each question scored from 0 to 3 \[0 = not at all and 3 = all the time\]). Total score for 22 questions range from 0 to 66 \[0 = worst condition and 66 = best well-being condition).
| scores on a scale | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18 | -1.43 ± 1.441 | 0.91 ± 1.04 |
Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6 | -4 ± 5.1 | -18.1 ± 3.7 |
Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6 | 4 ± 3.4 | 9.3 ± 2.4 |
Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6 | 3 ± 5.6 | -12.9 ± 4 |
Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18 | -1.2 ± 8 | -6.1 ± 5.9 |
Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 18 | 2.4 ± 5 | 10.9 ± 3.6 |
Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) |
|---|---|---|
| Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 18 | 4.1 ± 7.9 | -2.4 ± 5.8 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final study end visit (maximum duration: 46 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W (Double Blind Period) | 0/21 (0%) | 2/21 (9.5%) | 10/21 (47.6%) |
| Alirocumab 150 Q2W (Double Blind Period) | 0/41 (0%) | 4/41 (9.8%) | 22/41 (53.7%) |
| Alirocumab 150 Q2W (Open Label Treatment Period) | 0/29 (0%) | 1/29 (3.4%) | 2/29 (6.9%) |
| Event | Placebo Q2W (Double Blind Period) | Alirocumab 150 Q2W (Double Blind Period) | Alirocumab 150 Q2W (Open Label Treatment Period) |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/21 | 2/41 | 0/29 |
| Angina pectorisCardiac disorders | 1/21 | 0/41 | 0/29 |
| Sinus bradycardiaCardiac disorders | 1/21 | 0/41 | 0/29 |
| Shunt thrombosisInjury, poisoning and procedural complications | 1/21 | 0/41 | 0/29 |
| Myocardial ischaemiaCardiac disorders | 0/21 | 0/41 | 1/29 |
| Peripheral artery restenosisInjury, poisoning and procedural complications | 0/21 | 0/41 | 1/29 |
| Angina unstableCardiac disorders | 0/21 | 1/41 | 0/29 |
| Aortic valve stenosisCardiac disorders | 0/21 | 1/41 | 0/29 |
| Cardiac failure congestiveCardiac disorders | 0/21 | 1/41 | 0/29 |
| PneumoniaInfections and infestations | 0/21 | 1/41 | 0/29 |
| Event | Placebo Q2W (Double Blind Period) | Alirocumab 150 Q2W (Double Blind Period) | Alirocumab 150 Q2W (Open Label Treatment Period) |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/21 | 3/41 | 0/29 |
| FatigueGeneral disorders | 2/21 | 6/41 | 0/29 |
| NauseaGastrointestinal disorders | 3/21 | 2/41 | 0/29 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/21 | 5/41 | 0/29 |
| DiarrhoeaGastrointestinal disorders | 0/21 | 4/41 | 0/29 |
| NasopharyngitisInfections and infestations | 2/21 | 4/41 | 1/29 |
| PalpitationsCardiac disorders | 2/21 | 0/41 | 0/29 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/21 | 3/41 | 0/29 |
| Back painMusculoskeletal and connective tissue disorders | 2/21 | 2/41 | 0/29 |
| HeadacheNervous system disorders | 2/21 | 3/41 | 0/29 |
Analysis was performed on randomized population.
| Age, Continuous(years) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Mean | 57 ± 10.5 | 59.5 ± 9.2 | 58.7 ± 9.7 |
| Sex: Female, Male(Participants) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Female | 11 | 15 | 26 |
| Male | 10 | 26 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 21 | 41 | 62 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 21 | 39 | 60 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Frequency in which participants are undergoing LDL apheresis(Treatments) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Every week | 9 | 18 | 27 |
| Every 2 weeks | 12 | 23 | 35 |
| Calculated low-density lipoprotein cholesterol (LDL-C)(mg/dL) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Mean | 191.6 ± 68.9 | 175.1 ± 54.6 | 180.7 ± 59.7 |
| Measured LDL-C(mg/dL) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Mean | 195.0 ± 66.9 | 174.0 ± 51.4 | 181.1 ± 57.4 |
| Non-high-density lipoprotein cholesterol (HDL-C)(mg/dL) | Placebo Q2W (Double Blind Period) | Alirocumab 150 mg Q2W (Double Blind Period) | Total |
|---|---|---|---|
| Mean | 224.5 ± 68.0 | 210.3 ± 62.8 | 215.1 ± 64.4 |
6 further baseline measures are reported on the registry.
Ran from Mar 2015 to primary completion in Jan 2016, 10 months.
Results were first posted in May 2020, 4 years 3 months after primary completion. A results delay was requested in Jan 2017.
Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 10 months is below that.
Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab
Hyperlipoproteinemia Type II →